Comparison of efficacy of sibutramine or orlistat versus their combination in obese women

Endocrine Research

Volumn 30, Issue 2, 2004, Pages 159-167

  Sari, Ramazan ^a   Balci, Mustafa Kemal ^a   Cakir, Mehtap ^a   Altunbas, Hasan ^a   Karayalcin, Umit ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Obesity; Orlistat; Sibutramine; Treatment

Indexed keywords

SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CALORIE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EVALUATION; FEMALE; GLUCOSE TOLERANCE; HUMAN; LIPID BLOOD LEVEL; LIPID DIET; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CYCLOBUTANES; DIET, REDUCING; FEMALE; HUMANS; LACTONES; MIDDLE AGED; OBESITY; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 4544276140     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.1081/ERC-200027356     Document Type: Article

References (22)

1. Rossner S. Factors Determining the Long-Term Outcome of Obesity Treatment. Philadelphia: Lippincott Company, 1992.
2. Sjostrom CD, Lissner L, Sjostrom L. Relationship between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Obes Res 1997; 5:519-530.
3. Williamson DF, Pamuk E, Thun M, Flanders D, Byers T, Health C. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995; 141:1128-1141.
4. Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21:30S-36S.
5. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, Krempf M. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352:167-173.
6. Foster GD, Wadden TA, Vogt RA. What is a reasonable weight loss?: patients' expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997; 65:79-85.
7. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 2000; 20:805-875.
8. Weintraub M, Sundaresan PR, Madan M, Schuster B, Balder A, Lasagna L, Cox C. Long-term weight control study I (weeks 0 to 34): the enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992; 51:586-594.
9. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000; 8:431-437.
10. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998; 6(suppl 2):51S-209S.
11. Ashley FW Jr, Kannel WB. Relation of weight change to changes in atherogenic traits: the Framingham Study. J Chronic Dis 1974; 27:103-114.
12. Luque CA, Rey JA. Sibutramine: a serotonin re-uptake inhibitor for the treatment of obesity. Ann Pharmacother 1999; 33:968-978.
13. Atkinson RL, Blank RC, Schumacher D, Dhurandhar NV, Ritch DL. Long-term drug treatment of obesity in a private practice setting. Obes Res 1997; 5:578-586.
14. Kaya EA, Aydin N, Topsever P, Ozturk A, Dagar A. Comparison of efficacy of oral antiobesity treatment with sibutramine, orlistat and the combination of both on weight loss; preliminary results of a prospective randomized trial. 24th Congress of Endocrinology and Metabolic Diseases of Turkey Joint Meeting with the American Association of Clinical Endocrinologists, Istanbul, Endocrine Practice, 2001. Suppl, abstract: P87;68.
15. Guanglin W, Huimin Y, Xiuying Q, Zhenlin J. A case-control for the association between change in weight, family history and hypertension at different ages. Asia Pac J Public Health 2001; 13:96-99.
16. Vidal J. Updated review on the benefits of weight loss. Int J Obes Relat Metab Disord 2002; 26(suppl 4):S25-S28.
17. Laaksonen DE, Laitinen T, Schonberg J, Rissanen A, Niskanen LK. Weight loss and weight maintenance, ambulatory blood pressure and cardiac autonomic tone in obese persons with the metabolic syndrome. J Hypertens 2003; 21:371-378.
18. Wood PD, Stefanick M, Dreon DM, Wood PD, Stefanick ML, Dreon DM, Frey-Hewitt B, Garay SC, Williams PT, Superko HR, Fortmann SP, Albers JJ, Vranizan KM. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 1988; 319:1173-1179.
19. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1 year randomized double-blind study. Diabetes Care 1998; 21:1288-1294.
20. Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001; 286:1331-1339.
21. Pouliot MC, Despres JP, Lemieux S, Moorjani S, Bouchard C, Tremblay A, Nadeau A, Lupien PJ. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994; 73:460-468.
22. Van Gaal LF. Sibutramine trial of obesity reduction and maintenance-effects on risk factors. Int J Obes Relat Metab Disord 1998; 22(suppl 3):272.